BARICADE-PRESERVE Trial
Phase 3
300
about 2.3 years
1–35
5 sites in CO, FL, PA +2
What this study is about
Researchers are testing whether baricitinib can help preserve beta cell function in people newly diagnosed with type 1 diabetes. The trial will last about 60 weeks.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Baricitinib
- 2.Take Placebo
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
You may get a placebo/standard care, and you won't know which.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
baricitinib
oral (Oral Tablet)
Primary: Change from Baseline in C-peptide Area Under the Curve (AUC)
Secondary: Change from Baseline in Fasting C-Peptide, Change from Baseline in Height, Change from Baseline in Hemoglobin A1c (HbA1c), Change from Baseline in Matsuda Index, Change from Baseline in Mean Total Daily Insulin Dose, Change from Baseline in Number of Manual Insulin Boluses, Change from Baseline in Short Form 36 Version 2 Health Survey, Acute (SF-36v2), Pharmacokinetics (PK): Maximum Concentration (Cmax) of Baricitinib
Endocrinology